Результаты

medalphabet

Медицинский алфавит

Medical alphabet

2078-56312949-2807

ООО «Альфмед»

10.33667/2078-5631-2021-16-16-19

medalphabet-2136

Research Article

Статьи

Лефлуномид: современный взгляд на проблему безопасности (обзор литературы)

Leflunomide: modern look at safety problem (literature review)

https://orcid.org/0000-0002-0928-3911

Гриднева

Г. И.

Gridneva

G. I.

Гриднева Галина Игоревна, к.м.н., н.с. лаборатории изучения коморбидных инфекций и мониторинга безопасности лекарственной терапии

Gridneva Galina I., PhD Med, researcher at Dept of Comorbid Infections and Monitoring the Safety of Drug Therapy

https://orcid.org/0000-0002-1833-5357

Аронова

Е. С.

Aronova

E. S.

Аронова Евгения Сергеевна, к.м.н., н.с. лаборатории изучения коморбидных инфекций и мониторинга безопасности лекарственной терапии

Aronova Evgeniya S., PhD Med, researcher at Dept of Comorbid Infections and Monitoring the Safety of Drug Therapy

https://orcid.org/0000-0001-7880-631X

Кудрявцева

А. В.

Kudryavtseva

A. V.

Кудрявцева Анастасия Викторовна, н.с. лаборатории изучения коморбидных инфекций и мониторинга безопасности лекарственной терапии

Kudryavtseva Anastasia V., PhD Med, researcher at Dept of Comorbid Infections and Monitoring the Safety of Drug Therapy

https://orcid.org/0000-0001-7958-5926

Лукина

Г. В.

Lukina

G. V.

Лукина Галина Викторовна, д.м.н., проф., рук. научно-исследовательского отдела ревматологии; в.н.с. лаборатории изучения коморбидных инфекций и мониторинга безопасности лекарственной терапии

Lukina Galina V., DM Sci., professor, head of Research Division of Rheumatology; lead researcher at Dept of Comorbid Infections and Monitoring the Safety of Drug Therapy

ФГБНУ «Научно-исследовательский институт ревматологии имени В.А. Насоновой»РоссияV. A. Nasonova Research Institute of RheumatologyRussian Federation

ФГБНУ «Научно-исследовательский институт ревматологии имени В.А. Насоновой»; ГБУЗ «Московский клинический научно-практический центр имени А.С. Логинова Департамента здравоохранения Москвы»РоссияV. A. Nasonova Research Institute of Rheumatology; A. S. Loginov Moscow Clinical Scientific CenterRussian Federation

2021

18082021

016

Ревматология в общей врачебной практике

1619

2021

Гриднева Г.И., Аронова Е.С., Кудрявцева А.В., Лукина Г.В.

Gridneva G.I., Aronova E.S., Kudryavtseva A.V., Lukina G.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-alphabet.com/jour/article/view/2136

В соответствии с рекомендациями EULAR и АРР метотрексат (МТ) выступает препаратом первой линии терапии больных с ревматоидным артритом (РА). В тех случаях, когда применение МТ невозможно по причине его неэффективности или появления нежелательных реакций, в качестве первого базисного противовоспалительного препарата в рутинной клинической практике наиболее часто используются лефлуномид (ЛЕФ) или сульфасалазин.

Результаты

Результаты. В настоящей статье представлены обобщенные данные по безопасности препарата ЛЕФ при лечении пациентов с РА. Было показано, что нежелательные реакции, связанные с ЛЕФ, наиболее часто встречались в первый год лечения.

Выводы

Выводы. Наиболее частыми НЯ были: артериальная гипертензия, выпадение волос, жидкий стул, дерматиты различной локализации, повышение уровня трансаминаз, панцитопении и другие.

In accordance with the recommendations of EULAR and ARR methotrexate (MTX) is the first-line drug in patients with rheumatoid arthritis (RA). In cases where the use of MTX is impossible due to its ineffectiveness or adverse drug reactions (ADRs), leflomide (LEF) or sulfasalazine is most commonly used in routine clinical practice. This article presents generalized data on the safety of LEF in the treatment of patients with RA. It was shown that ADRs associated with the LEF were most often met in the first year of treatment. The most frequent ADRs were arterial hypertension, hair loss, diarrhea, dermatitis of different localization, increasing the level of transaminases, pancytopenia and others.

лефлуномидбезопасностьревматоидный артритотмена

leflunomidesafetyrheumatoid arthritiscancellation of therapy

References1

Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases 2020; 79: 685–699.

Насонов Е.Л., редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. С. 17–57.

Nasonov EL, editor. Russian clinical guidelines. Rheumatology. Moscow: GEOTAR-Media; 2017. P. 17–57 (In Russ.)

Singh JA, Furst D, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012; 64: 625–39. DOI: 10.1002/acr.21641.

Xu X, Williams JW, Gong H, et al. Two activities of the immunosuppressive metabolite of leflunomide, A771726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem Pharmacol. 1996 Aug 23; 52 (4): 527–34. DOI: http://dx.doi. org/10.1016/0006–2952(96)00303–6.

Grisar J, Aringer M, Koller MD, et al. Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells. Ann Rheum Dis. 2004 Dec; 63 (12): 1632–7. DOI: http://dx.doi.org/10.1136/ard.2003.018440.

Elkayam O, Yaron I, Shirazi I, Judovitch R, Caspi D, Yaron M. Active leflunomide metabolite inhibits interleukin 1beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase 3 production in activated human synovial tissue cultures. Ann Rheum Dis. 2003; 62 (5): 440–443. DOI: 10.1136/ard.62.5.440.

Burger D, Begué-Pastor N, Benavent S, Gruaz L, Kaufmann MT, Chicheportiche R, Dayer JM. The active metabolite of leflunomide, A771726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes. Rheumatology (Oxford). 2003 Jan; 42 (1): 89–96. DOI: 10.1093/rheumatology/keg038.

Kraan MC, de Koster BM, Elferink JG, Post WJ, Breedveld FC, Tak PP. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum. 2000 Jul; 43 (7): 1488–95. DOI: 10.1002/1529– 0131(200007)43:73.0.CO;2-G.

Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A771726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol. 1999 Feb 15; 162 (4): 2095–102. PMID: 9973483.

Alcorn N, Saunders S, Madhok R: Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 2009; 32: 1123–34.

Чичасова Н.В. Оценка эффективности и переносимости лефлуномида (элафра) у больных ревматоидным артритом по данным открытого многоцентрового исследования. Научно-практическая ревматология. 2018; 56 (4): 466–473. https://doi. org/10.14412/1995–4484–2018–466–473

Chichasova N.V. Evaluation of the efficacy and tolerability of leflunomide (elafra) in patients with rheumatoid arthritis according to an open multicenter study. Scientific and practical rheumatology. 2018; 56 (4): 466–473. https://doi.org/10.14412/1995–4484–2018–466–473.

Федоренко Е.В., Лукина Г.В., Сигидин Я.А., Каратеев Д.Е., Насонов Е.Л. Сравнительная эффективность современных методов терапии раннего ревматоидного артрита (предварительные результаты). Научно-практическая ревматология. 2008; 46 (4): 36–40. DOI: 10.14412/1995–4484–2008–534.

Fedorenko E.V., Lukina G.V., Sigidin Ya.A., Karateev D.E., Nasonov E.L. Comparative effectiveness of modern methods of treatment of early rheumatoid arthritis (preliminary results). Scientific and practical rheumatology. 2008; 46 (4): 36–40. DOI: 10.14412 / 1995–4484–2008–534.

Aletaha D, Stamm T, Kapral T et al.: Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 2003; 62: 944–51.

Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg JD, Kavanaugh A, Reed G, Strand V, Kremer JM. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis. 2010 Jan; 69 (1): 43–7. DOI: 10.1136/ard.2008.101378.

Rutanen J, Kononoff A, Arstila L, Elfving P, Koskela H, Kaipiainen-Seppänen O. Five cases of interstitial lung disease after leflunomide was combined with methotrexate therapy. Scand J Rheumatol. 2014; 43 (3): 254–6. DOI: 10.3109/03009742.2013.868511. Epub 2014 Mar 21. PMID: 24650220.

Jenks KA, Stamp LK, O'Donnell JL, Savage RL, Chapman PT. Leflunomide-associated infections in rheumatoid arthritis. J Rheumatol. 2007 Nov; 34 (11): 2201–3. Epub 2007 Oct 15. PMID: 17937473.

Hill RL, Topliss DJ, Purcell PM. Pancytopenia associated with leflunomide and methotrexate. Annals of Pharmacotherapy. 2003; 37 (1): p. 149.

McEwen J, Purcell PM, Hill RL, Calcino LJ, Riley CG. The incidence of pancytopenia in patients taking leflunomide alone or with methotrexate. Pharmacoepidemiology and Drug Safety. 2007; 16 (1): 65–73.

Chan J, Sanders DC, Du L, Pillans PI. Leflunomide-associated pancytopenia with or without methotrexate. Annals of Pharmacotherapy. 2004; 38 (7–8): 1206–1211.

Lee SW, Park HJ, Kim BK, et al. Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. Arthritis Research & Therapy. 2012;14 (5): p. R232.

Londono J, Santos AM, Santos PI, Cubidez MF, Guzman C, Valle-Oñate R. Therapeutic efficacy and safety of methotrexate + leflunomide in Colombian patients with active rheumatoid arthritis refractory to onventional treatment. Revista Brasileira de Reumatologia. 2012; 52 (6): 837–845.

Bird P, Griffiths H, Tymms K, Nicholls D, Roberts L, Arnold M, Burnet S, de Jager J, Scott J, Zochling J, Littlejohn G. The SMILE study – safety of methotrexate in combination with leflunomide in rheumatoid arthritis. J Rheumatol. 2013 Mar; 40 (3): 228–35. DOI: 10.3899/ jrheum.120922. Epub 2013 Jan 15. PMID: 23322457.

Arava (Leflunomide) Sanofi-Aventis. UK Summary of product characteristics, September 2009.

Jian Lu, Xuyang Shang, Weiguo Zhong, Yuan Xu, Rong Shi, Xin Wang. New insights of CYP1A in endogenous metabolism: a focus on single nucleotide polymorphisms and diseases, Acta Pharmaceutica Sinica B 2020; 10 (1): 91e104. https://doi.org/10.1016/j. apsb.2019.11.016.

Kalgutkar AS, Nguyen HT, Vaz AD In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. Drug Metab Dispos 2003; 31: 1240–50.

Grabar Pb, Rozman B, Tomsic M, Suput D, Logar D, Dolzan V: Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 2008; 64: 871–6.

Hopkins, A.M.; Wiese, M.D.; Proudman, S.M.; O’Doherty, C.E.; Upton, R.N.; Foster, D.J.R. Genetic Polymorphism of CYP1A2 but Not Total or Free Teriflunomide Concentrations Is Associated with Leflunomide Cessation in Rheumatoid Arthritis. Br.J. Clin. Pharmacol. 2016, 81, 113–123.

Pawlik A, Herczynska M, Kurzawski M, Safranow K, Dziedziejko V, Drozdzik M: The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide. Pharmacogenomics 2009; 10: 303–9.

Grabar P, Grabnar I, Rozman B et al.: Investigation of this influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-cyano 3-hydroxy-N-(4-(trifluoromethyl)-2-butenamide (A771726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. Drug Metab Dispos 2009; 37: 2061–8.

Wiese M, Schnabl M, O’Doherty C et al.: Polymorphisms in cytochrome P450 2C 19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. Arthritis Res Ther 2012; 14: R163.

Kvien T, Uhlig T, Ødegård S, Heiberg M: Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann N Y Acad Sci 2006; 1069: 212–22.

Sokka T, Toloza S, Cutolo M et al.: Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther 2009; 11: R7.

Montagna P, Soldano S, Brizzolara R et al.: Estrogens interfere with leflunomide modulation of cytokine production by human activated monocytes. Ann N Y Acad Sci 2010; 1193: 30–5.

Cutolo M, Montagna P, Brizzolara R et al.: Sex hormones modulate the effects of Leflunomide on cytokine production by cultures of differentiated monocyte/macrophages and synovial macrophages from rheumatoid arthritis patients. J Autoimmun 2009; 32: 254–60.

Dziedziejko V, Kurzawski M, Safranow K, Chlubek D, Pawlik A: The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide. Pharmacogenomics 2011; 12: 41–7.

The authors declare that there are no conflicts of interest present.